ASHLAND INC. (ASH): what the price requires

At today's price, ASHLAND INC. (ASH) is priced for today's economics sustained for ~9.7 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/ASH

Headline

FieldValue
TickerASH
CompanyASHLAND INC.
Current price$65.58/sh
CompositionLife Sciences 35% / Personal Care 32% / Specialty Additives 28% / Intermediates 8% / Intersegment sales -2%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (mid-cycle)3.0%
Trailing margin (depressed year)-34.5%
Must persist for9.7y
Multiple paid76x mid-cycle operating income

Solve inputs: computed at a 7.9% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.4 years.

Reconcile: at the x-ray's 9.3% required return this reads ~13 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.49σ
sustained it ~9.7 years at this level14%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple; asset-based/earnings-power/growth-DCF land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.80x3expensive
Earnings10.70x1expensive
Relative0.67x3justifies
Growth8.53x2expensive

Families that justify the price: Relative Families that call it expensive: Asset, Earnings, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.4%); the inversion above states its own rate.

Per-Model Detail (n=9)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$98.260.67xyesP/S fallback (negative EPS): Sector P/S 2.5x × TTM revenue — excluded from consensus
Simple DDMGrowth$4.3515.07xyesDPS $3.30, g=-37.9% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3%
Two-Stage DDMGrowth$-40.81—noStage 1: -200% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$40.571.62xyesReference only (book value floor): BV/sh $40.57, ROE negative
Two-Stage Excess ReturnAsset$36.511.80xyesReference only (book value with convergence): BV/sh $40.57, ROE converges to ke
Discounted Future Market CapGrowth$33.151.98xyesRev $1.8B, growth -7% (input: historical growth; tapered), Terminal P/S: 1.4x / 1.7x / 1.9x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$6.1310.70xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.14B × (1−25%) / WACC 7.4% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$62.981.04xyesEBITDA $0.34B × sector EV/EBITDA 12.0x
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset$5.3112.35xyesBV $40.57 × (ROIC 1.0% / WACC 7.4%)
P/Sales SectorRelative$98.260.67xyesRevenue $1.81B × sector P/S 2.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$1.1b
Net debt / NOPAT (after-tax)26.27x
Net debt / operating income (pre-tax)19.70x
Share count CAGR (buyback)-5.2%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 3.0%); the trailing year was depressed.

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

Read Ashland as a quality specialty franchise caught in a cyclical and operational trough, because that frame changes how you weigh the numbers. The trailing operating margin is deeply negative, but that is the work of a non-cash impairment, not the cash economics of the business. Strip it out and the underlying engine still earned an adjusted EBITDA margin near 20% in fiscal Q2 2026, even in a soft quarter. A 20% margin in a demand downturn is the signature of a business with pricing power and differentiated products, not a commodity producer.

The quality sits in the mix. Life Sciences and Personal Care together are roughly two-thirds of revenue, and the filing describes Ashland serving end markets that include "food and beverage, personal care and pharmaceutical" across more than 100 countries. These are formulation businesses where Ashland's ingredients are small, specified components of a customer's recipe, hard to switch out and tied to the customer's own product registrations. Management noted resilient commercial performance with strong execution in exactly these segments even as the cyclical parts of the portfolio sagged. That is the defensible core that should carry the business through the cycle.

The self-help is the bridge to recovery. Ashland is executing a restructuring program targeting about $30 million of savings in fiscal 2026 and a cumulative $50 to $60 million, and the benefits are already showing up in lower overhead. The company also pays a dividend yielding nearly 5% at the current price, supported by the cash the specialty segments throw off. The methods anchored on the business's normalized earning power and peer multiples land above the current price, with an EV-to-EBITDA comparison near $63 and a peer revenue multiple higher still. The bull case is a high-margin specialty franchise trading near its book-value floor while a temporary impairment, plant scale-up issues, and a demand cycle obscure the real earning power that the restructuring is sharpening.

Bear Case

The variables doing the most damage to Ashland's thesis are macro and operational, and several are outside management's control. The fiscal 2026 guidance cut was driven by a cluster of external pressures: softer energy-related demand tied to Middle East conflict, reduced electric-vehicle-driven demand for the company's BDO-based derivatives, and weather disruptions, with a plant startup delay and weather alone costing roughly $10 million of adjusted EBITDA in the quarter. A specialty chemical maker is a price-taker on its raw materials and a demand-taker from its customers' end markets, so a downturn in autos, energy, or construction flows straight to the bottom line. Adjusted EBITDA fell 9% year over year with the margin down 220 basis points, the wrong direction.

The regulatory and input-cost exposure compounds the cyclicality. The filing flags that disruptions to "raw materials to the Company" could have "significant impacts to pricing," and that climate-driven coastal storms threaten manufacturing sites. It also notes "increasing pressure to innovate" around bio-based materials to stay competitive, a reminder that even differentiated chemistry faces substitution and reformulation risk over time. Environmental regulation, tariffs on globally sourced inputs, and customer destocking are all live variables that the current price, sitting well above the asset floor, does not obviously discount.

The balance sheet leaves less cushion than the dividend yield suggests. Net debt is over $1 billion, and with operating profit depressed by the impairment and the cycle, leverage looks heavy against current earnings. The price embeds roughly a decade of growth held at the firm's ceiling on normalized earnings, a demanding bar for a business whose revenue is currently declining and whose guidance is moving down, not up. The asset-based methods land near a book value of about $40 a share, well below the current price, which is the floor the bear points to. If the demand recovery stalls, the plant scale-ups keep slipping, or another impairment follows, the gap between the price and that asset floor is the downside, and the leverage means it would not be a gentle one.

Valuation

Ashland has to be valued on normalized earnings, because the trailing figures are distorted by a non-cash impairment that turned the reported operating margin sharply negative. On the company's own through-the-cycle margins applied to current revenue, the price works out to roughly 78 times normalized operating income, which implies growth held near the firm's ceiling for about a decade. Keep that approximate; it is one solve under fixed assumptions, and its reliability is limited given the depressed cycle. The honest reading is that on normalized economics the price is full, paying for a recovery that has not yet arrived.

The methods scatter because the trough distorts several of them. The asset family, anchored on a book value of about $40 a share, lands near $36 to $40, below the price; that is the floor. The peer-multiple family is mixed and depends heavily on the multiple chosen: an EV-to-EBITDA comparison lands near $63, just below the price, while a sector revenue multiple lands near $98, above it. The earnings-power method is unreliable here because normalized operating income is depressed. Read together, the price sits above its asset floor and around its EV-to-EBITDA-implied value, with the bull-case upside resting on the peer revenue multiple and a margin recovery. This is a name where the spread between methods is wide precisely because the cycle makes the inputs noisy.

Solvency deserves real weight. Net debt of over $1 billion is meaningful against earnings that the cycle and the impairment have suppressed, which is why the leverage ratios look stretched on trailing numbers. The dividend, yielding near 5%, is supported by the specialty segments' cash but is one more claim on capital in a soft period. The decisive question the valuation poses is whether the high-margin Life Sciences and Personal Care core, plus the restructuring savings, can lift normalized earnings back toward mid-cycle levels. If they do, the EV-to-EBITDA and revenue-multiple methods above the price frame the upside; if the trough persists, the book-value floor near $40 is the reminder of where support sits.

Catalysts

Fiscal second-quarter 2026 results, reported in late April, came with a guidance cut. Sales rose 1% to $482 million, but net income fell to $16 million, or $0.34 a diluted share, from $31 million a year earlier, and adjusted EBITDA fell 9% to $98 million at a 20% margin, down 220 basis points. Management lowered full-year fiscal 2026 sales guidance to $1,835 million to $1,870 million and adjusted EBITDA guidance to $385 million to $400 million. These are company-defined measures; the GAAP result is the relevant one for trailing comparisons.

The forward catalysts are operational recovery and restructuring. The cut reflected productivity problems in the Hopewell scale-up, a Calvert City startup delay, weather disruptions costing roughly $10 million of EBITDA, and softer energy and electric-vehicle-related demand. Offsetting that, the company is targeting about $30 million of restructuring savings in fiscal 2026, building toward a cumulative $50 million to $60 million, with potential upside if China demand recovers. The metrics to watch over the coming quarters are whether the plant scale-ups stabilize, whether the high-margin Personal Care and Life Sciences segments keep executing, and whether restructuring savings and a demand recovery move adjusted EBITDA back toward the mid-cycle level the price requires.

Peer Cohorts (Per Segment, With Filing Citations)

Life Sciences (reported)

Personal Care (reported)

Specialty Additives (reported)

Intermediates (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q2 FY2026 results, April 2026 · FY2025 10-K

View the full interactive ASH report on boothcheck